바이러스 클리어런스 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of viral clearance Market

The global viral clearance market size was valued at USD 834.1 million in 2025 and is projected to grow from USD 971.65 million in 2026 to USD 3,804.75 million by 2034, exhibiting a strong CAGR of 18.60% during the forecast period (2026-2034). North America dominated the market with a 37.50% share in 2025, supported by a well-established biotechnology ecosystem and rising clinical trial activity.

Viral clearance studies are critical in the development and manufacturing of biologics derived from plants, animals, or humans, as these products are highly susceptible to viral contamination. These studies ensure the safety and purity of vaccines, recombinant proteins, blood products, and cell & gene therapies. With global vaccine production reaching nearly 5.0 billion doses annually, the demand for viral safety testing continues to increase. Although the market witnessed slower growth during the COVID-19 lockdown phase, recovery in 2021 was driven by increased vaccine development and clinical research.

Market Dynamics

Market Drivers

Rising Biopharmaceutical R&D Expenditure

The growing burden of chronic diseases such as cardiovascular disorders, cancer, and diabetes has intensified the need for biologics. According to WHO, cancer accounted for 10 million deaths globally in 2020. To address this, pharmaceutical companies are increasing R&D spending. For instance, PhRMA member companies invested USD 102.3 billion in R&D in 2022. As viral clearance is mandatory for biologics approval, increasing R&D directly fuels demand for these services.

Stringent Regulatory Requirements

Global regulatory bodies, including the International Council for Harmonisation (ICH), have issued strict guidelines on viral safety evaluation for biotechnology products. Compliance with IND and BLA submission standards has made viral clearance testing an essential part of biologics development, thereby driving market growth.

Market Trends

Facility Expansion by Key Players

Leading service providers are expanding viral clearance laboratories to meet growing global demand. For example, in September 2022, Merck KGaA opened a viral clearance laboratory in China as part of its Biologics Testing Center. Similarly, companies such as WuXi Biologics and Texcell have expanded testing facilities to enhance service capabilities. These expansions improve accessibility for pharmaceutical and biotech firms and support the rapid development of vaccines and advanced therapies.

Restraining Factors

High Cost of Advanced Technologies

Viral clearance studies require sophisticated analytical systems such as chromatography and high-performance liquid chromatography (HPLC). Equipment costs can range from USD 30,000 to USD 100,000, creating financial barriers for smaller firms. Additionally, competition for highly skilled scientists increases operational costs, limiting adoption among small-scale providers.

Segmentation Analysis

By Method

The market is segmented into viral removal, viral inactivation, and viral detection.

The viral removal method segment dominated in 2026, driven by increasing demand for vaccines and biologics and strong R&D investments. Techniques such as chromatography and filtration are widely used due to their efficiency.

The viral inactivation segment is projected to grow steadily, supported by rising approvals of plasma proteins and gene therapy products. Meanwhile, viral detection methods, including PCR and next-generation sequencing (NGS), are expected to grow at a considerable CAGR due to their essential role in identifying viral contaminants.

By Application

Based on application, the market includes vaccines, blood & blood products, recombinant proteins, cellular & gene therapy products, and others.

The vaccines segment dominated in 2026, fueled by growing immunization coverage and demand for protection against infectious and chronic diseases. For example, global measles vaccine coverage increased to 83% in 2022.

The blood & blood products segment is anticipated to expand substantially, supported by approximately 118.5 million blood donations collected worldwide annually. The cellular & gene therapy segment is expected to grow at the highest CAGR due to increasing use of advanced therapies in treating rare and chronic conditions.

By End-user

The market is segmented into pharmaceutical & biotech industry, CROs, academic research institutes, and others.

The pharmaceutical & biotech industry segment dominated in 2026, as viral safety testing is mandatory for biologics manufacturing. CROs are projected to grow significantly due to increased outsourcing of testing services. Academic and research institutes are also expected to witness strong growth, driven by expanding drug discovery research initiatives.

Regional Insights

North America

North America accounted for USD 312.7 million in 2025, maintaining leadership due to strong pharmaceutical manufacturing capacity and increasing clinical trials. The U.S. recorded a rise in registered clinical trials from 7,462 in 2010 to 9,901 in 2022, strengthening demand for viral clearance services.

Europe

Europe is the second-largest market, supported by a strong biotechnology foundation and rising R&D spending. Companies such as CRISPR Therapeutics invested USD 461.6 million in R&D in 2022, contributing to regional expansion.

Asia Pacific

Asia Pacific is projected to grow rapidly due to increased generics manufacturing, funding for medical research, and expansion of CROs. China and Japan are strengthening domestic biopharmaceutical production capabilities, boosting demand for viral clearance services.

Latin America and the Middle East & Africa are expected to witness gradual growth due to rising healthcare expenditure and biologics adoption.

Competitive Landscape

Key market players include Merck KGaA, Charles River Laboratories, WuXi Biologics, Texcell, Sartorius AG, Kedrion, Clean Cells, ViruSure GmbH, and Syngene International. These companies focus on facility expansion, acquisitions, and service portfolio enhancement to strengthen market presence.

Recent developments include:

• June 2023: Texcell expanded its viral clearance facility in the U.S.
• December 2022: WuXi Biologics opened a Biosafety Testing Center in Shanghai.
• December 2021: ViruSure acquired Bionique Testing Laboratories to enhance service offerings.

Conclusion

The global viral clearance market is poised for robust expansion, growing from USD 834.1 million in 2025 to USD 971.65 million in 2026, and projected to reach USD 3,804.75 million by 2034, at a remarkable CAGR of 18.60%. Increasing biologics development, stringent regulatory requirements, expanding R&D investments, and facility expansions by key players are primary growth drivers. Despite high technology costs and talent shortages, the rising global demand for safe and effective biopharmaceuticals will continue to propel long-term market growth.

Segmentation By Method

• Viral Removal Method
  • Chromatography
  • Filtration
  • Precipitation
• Viral Inactivation Method
  • pH Modification
  • Solvent Detergent (S/D)
  • Pasteurization
  • Dry Heat
  • Others
• Viral Detection Method
  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • In vivo Assay
  • In vitro Assay
  • Others

By Application

• Blood and Blood Products
• Recombinant Proteins
• Cellular & Gene Therapy Products
• Vaccines
• Others

By End-user

• Pharmaceutical and Biotech Industry
• Academic Research Institutes
• CROs
• Others

By Geography

• North America (By Method, Application, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Method, Application, End-user, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Method, Application, End-user, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Method, Application, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Method, Application, End-user, and Country/Sub-region)
  • South Africa
  • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Technological Advancements
• 4.2. Key Industry Trends
• 4.3. Regulatory Scenario
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Method
  • 5.1.1. Viral Removal Method
    • 5.1.1.1. Chromatography
    • 5.1.1.2. Filtration
    • 5.1.1.3. Precipitation
  • 5.1.2. Viral Inactivation Method
    • 5.1.2.1. pH Modification
    • 5.1.2.2. Solvent Detergent (S/D)
    • 5.1.2.3. Pasteurization
    • 5.1.2.4. Dry Heat
    • 5.1.2.5. Others
  • 5.1.3. Viral Detection Method
    • 5.1.3.1. Next Generation Sequencing (NGS)
    • 5.1.3.2. Polymerase Chain Reaction (PCR)
    • 5.1.3.3. In vivo Assay
    • 5.1.3.4. In vitro Assay
    • 5.1.3.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Applications
  • 5.2.1. Blood and Blood Products
  • 5.2.2. Recombinant Proteins
  • 5.2.3. Cellular & Gene Therapy Products
  • 5.2.4. Vaccines
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Pharmaceutical and Biotech Industry
  • 5.3.2. Academic Research Institutes
  • 5.3.3. CROs
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Geography
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Method
  • 6.1.1. Viral Removal Method
    • 6.1.1.1. Chromatography
    • 6.1.1.2. Filtration
    • 6.1.1.3. Precipitation
  • 6.1.2. Viral Inactivation Method
    • 6.1.2.1. pH Modification
    • 6.1.2.2. Solvent Detergent (S/D)
    • 6.1.2.3. Pasteurization
    • 6.1.2.4. Dry Heat
    • 6.1.2.5. Others
  • 6.1.3. Viral Detection Method
    • 6.1.3.1. Next Generation Sequencing (NGS)
    • 6.1.3.2. Polymerase Chain Reaction (PCR)
    • 6.1.3.3. In vivo Assay
    • 6.1.3.4. In vitro Assay
    • 6.1.3.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Applications
  • 6.2.1. Blood and Blood Products
  • 6.2.2. Recombinant Proteins
  • 6.2.3. Cellular & Gene Therapy Products
  • 6.2.4. Vaccines
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Pharmaceutical and Biotech Industry
  • 6.3.2. Academic Research Institutes
  • 6.3.3. CROs
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Method
  • 7.1.1. Viral Removal Method
    • 7.1.1.1. Chromatography
    • 7.1.1.2. Filtration
    • 7.1.1.3. Precipitation
  • 7.1.2. Viral Inactivation Method
    • 7.1.2.1. pH Modification
    • 7.1.2.2. Solvent Detergent (S/D)
    • 7.1.2.3. Pasteurization
    • 7.1.2.4. Dry Heat
    • 7.1.2.5. Others
  • 7.1.3. Viral Detection Method
    • 7.1.3.1. Next Generation Sequencing (NGS)
    • 7.1.3.2. Polymerase Chain Reaction (PCR)
    • 7.1.3.3. In vivo Assay
    • 7.1.3.4. In vitro Assay
    • 7.1.3.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Applications
  • 7.2.1. Blood and Blood Products
  • 7.2.2. Recombinant Proteins
  • 7.2.3. Cellular & Gene Therapy Products
  • 7.2.4. Vaccines
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Pharmaceutical and Biotech Industry
  • 7.3.2. Academic Research Institutes
  • 7.3.3. CROs
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Method
  • 8.1.1. Viral Removal Method
    • 8.1.1.1. Chromatography
    • 8.1.1.2. Filtration
    • 8.1.1.3. Precipitation
  • 8.1.2. Viral Inactivation Method
    • 8.1.2.1. pH Modification
    • 8.1.2.2. Solvent Detergent (S/D)
    • 8.1.2.3. Pasteurization
    • 8.1.2.4. Dry Heat
    • 8.1.2.5. Others
  • 8.1.3. Viral Detection Method
    • 8.1.3.1. Next Generation Sequencing (NGS)
    • 8.1.3.2. Polymerase Chain Reaction (PCR)
    • 8.1.3.3. In vivo Assay
    • 8.1.3.4. In vitro Assay
    • 8.1.3.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Applications
  • 8.2.1. Blood and Blood Products
  • 8.2.2. Recombinant Proteins
  • 8.2.3. Cellular & Gene Therapy Products
  • 8.2.4. Vaccines
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Pharmaceutical and Biotech Industry
  • 8.3.2. Academic Research Institutes
  • 8.3.3. CROs
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Method
  • 9.1.1. Viral Removal Method
    • 9.1.1.1. Chromatography
    • 9.1.1.2. Filtration
    • 9.1.1.3. Precipitation
  • 9.1.2. Viral Inactivation Method
    • 9.1.2.1. pH Modification
    • 9.1.2.2. Solvent Detergent (S/D)
    • 9.1.2.3. Pasteurization
    • 9.1.2.4. Dry Heat
    • 9.1.2.5. Others
  • 9.1.3. Viral Detection Method
    • 9.1.3.1. Next Generation Sequencing (NGS)
    • 9.1.3.2. Polymerase Chain Reaction (PCR)
    • 9.1.3.3. In vivo Assay
    • 9.1.3.4. In vitro Assay
    • 9.1.3.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Applications
  • 9.2.1. Blood and Blood Products
  • 9.2.2. Recombinant Proteins
  • 9.2.3. Cellular & Gene Therapy Products
  • 9.2.4. Vaccines
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Pharmaceutical and Biotech Industry
  • 9.3.2. Academic Research Institutes
  • 9.3.3. CROs
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Viral Clearance Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Method
  • 10.1.1. Viral Removal Method
    • 10.1.1.1. Chromatography
    • 10.1.1.2. Filtration
    • 10.1.1.3. Precipitation
  • 10.1.2. Viral Inactivation Method
    • 10.1.2.1. pH Modification
    • 10.1.2.2. Solvent Detergent (S/D)
    • 10.1.2.3. Pasteurization
    • 10.1.2.4. Dry Heat
    • 10.1.2.5. Others
  • 10.1.3. Viral Detection Method
    • 10.1.3.1. Next Generation Sequencing (NGS)
    • 10.1.3.2. Polymerase Chain Reaction (PCR)
    • 10.1.3.3. In vivo Assay
    • 10.1.3.4. In vitro Assay
    • 10.1.3.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Applications
  • 10.2.1. Blood and Blood Products
  • 10.2.2. Recombinant Proteins
  • 10.2.3. Cellular & Gene Therapy Products
  • 10.2.4. Vaccines
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Pharmaceutical and Biotech Industry
  • 10.3.2. Academic Research Institutes
  • 10.3.3. CROs
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Merck KGaA
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Wuxi Biologics
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Charles River Laboratories
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Texcell
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Vironova
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Kedrion
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Clean Cells
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. ViruSure GmbH
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Sartorius AG
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Syngene International Limited
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Microbiologics
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)